Measurement of spleen stiffness (SS) may be utilized to assess the risk of a hepatic decompensation and may therefore be used a robust screening tool to identify patients who need closer monitoring, suggests a study. In addition, SS can differentiate between acute and chronic or acute on chronic liver damage.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).
Long-term treatment with β blockers improves decompensation-free survival in patients with compensated cirrhosis and clinically significant portal hypertension (CSPH), according to the PREDESCI* study, which heralds a new youth for β blockers conventionally used for treating primary hypertension.
Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress™ (ILC 2019).
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress™ (ILC 2019).
Survival and recurrence outcomes of liver resection (LR) are comparable among patients with spontaneous rupture (sr) and nonruptured (nr) hepatocellular carcinoma (HCC), according to a recent Singapore study.
Patients with chronic hepatitis B virus (HBV) infection treated with the nucleot(s)ide analogue tenofovir disoproxil fumarate (TDF) had a lower risk of hepatocellular carcinoma (HCC) than those treated with entecavir, according to data from a large observational study presented at ILC 2019.
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.